{"organizations": [], "uuid": "c34cee16557cb2d5f65b364c3f3dbdad85db9520", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-prometics-pbi-4050-phase-3-pivotal/brief-prometics-pbi-4050-phase-3-pivotal-clinical-trial-design-for-idiopathic-pulmonary-fibrosis-finalized-idUSASB0C2OJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Prometic's Pbi-4050 Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis Finalized", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.861, "site_type": "news", "published": "2018-01-29T20:06:00.000+02:00", "replies_count": 0, "uuid": "c34cee16557cb2d5f65b364c3f3dbdad85db9520"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-prometics-pbi-4050-phase-3-pivotal/brief-prometics-pbi-4050-phase-3-pivotal-clinical-trial-design-for-idiopathic-pulmonary-fibrosis-finalized-idUSASB0C2OJ", "ord_in_thread": 0, "title": "BRIEF-Prometic's Pbi-4050 Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis Finalized", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "prometic life sciences inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC‘S PBI-4050: PHASE 3 PIVOTAL CLINICAL TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) FINALIZED\n* PROMETIC LIFE SCIENCES - BASED ON RECOMMENDATIONS FROM FDA, CO NOW WILL UNDERTAKE AN “ALL COMERS STUDY”\n* PROMETIC - PBI-4050 STUDY WILL ENROLL PATIENTS WITH MILD-TO-MODERATE IPF, REGARDLESS OF BACKGROUND STANDARD OF CARE WITH NINTEDANIB OR NOT Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T20:06:00.000+02:00", "crawled": "2018-01-30T19:13:39.000+02:00", "highlightTitle": ""}